ITCI:NSD-Intra-Cellular Therapies Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 56.96

Change

-1.45 (-2.48)%

Market Cap

USD 5.46B

Volume

0.54M

Avg Analyst Target

USD 60.78 (+6.70%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Intra-Cellular Therapies Inc (ITCI) Stock Analysis:
Based on the Intra-Cellular Therapies Inc stock forecasts from 6 analysts, the average analyst target price for Intra-Cellular Therapies Inc is USD 60.78 over the next 12 months. Intra-Cellular Therapies Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Intra-Cellular Therapies Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Intra-Cellular Therapies Inc’s stock price was USD 56.96. Intra-Cellular Therapies Inc’s stock price has changed by -4.12% over the past week, +8.62% over the past month and +48.80% over the last year.

About

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for t ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

-1.89 (-2.19%)

USD8.24B 118.05 62.27
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
PCRX Pacira BioSciences Inc

-2.46 (-3.90%)

USD2.89B 75.79 27.19
TLRY Tilray Inc

-0.23 (-5.12%)

USD2.35B 49.17 N/A
CGC Canopy Growth Corporation

-0.43 (-8.29%)

USD2.32B N/A N/A
IRWD Ironwood Pharmaceuticals Inc

-0.30 (-2.64%)

USD1.75B 3.70 6.95
AMPH Amphastar Pharmaceuticals Inc

-0.86 (-2.47%)

USD1.70B 21.47 11.51
HCM HUTCHMED (China) Limited

-1.02 (-10.61%)

USD1.66B 17.69 N/A

ETFs Containing ITCI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.83% 89% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.83% 89% B+ 93% A
Trailing 12 Months  
Capital Gain 48.64% 96% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.64% 96% A 96% A
Trailing 5 Years  
Capital Gain 442.99% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 442.99% 95% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 46.40% 87% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.40% 87% B+ 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 69.14% 31% F 20% F
Risk Adjusted Return 67.11% 100% A+ 89% B+
Market Capitalization 5.46B 99% A+ 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.96 16% F 11% F
Price / Cash Flow Ratio -21.03 94% A 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -43.21% 63% D 26% F
Return on Invested Capital -53.16% 38% F 19% F
Return on Assets -24.72% 34% F 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.65 59% F 44% F
Short Percent 4.07% 66% D 40% F
Beta 1.28 39% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector